GlassScriptPhysician profile
Sandeep Anreddy
NPI 1326257692
$1,665.22
in general payments reported to CMS, 2019-2025
25 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.55 · 2021: $15.53 · 2022: $552 · 2023: $400 · 2024: $168 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $301.90 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.39 | 2022-2023 | Jardiance |
| Abiomed | $176.15 | 2024-2025 | Impella |
| Merck Sharp & Dohme LLC | $170.71 | 2022-2023 | Verquvo |
| Astellas Pharma US INC | $146.40 | 2022 | |
| Amgen INC. | $116.36 | 2023-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $78.59 | 2025 | Assure Wcd |
| Atricure, INC. | $67.54 | 2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| E.R. Squibb & Sons, L.L.C. | $50.76 | 2023-2025 | Eliquis, Camzyos |
| Pfizer INC. | $36.50 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $34.21 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $31.52 | 2022-2023 | Onpattro |
| Daiichi Sankyo INC. | $26.53 | 2022 | |
| Ge Healthcare | $24.84 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $24.52 | 2023 | Uptravi, Opsumit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $24.45 | 2025 | Barostim Neo System |
| Abbott Laboratories | $21.49 | 2022 | |
| Cardiva Medical, INC. | $19.26 | 2019 | |
| Altathera Pharmaceuticals LLC | $18.69 | 2024 | Sotalol Hydrochloride |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.16 | 2025 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $17.57 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $15.99 | 2024 | |
| Esperion Therapeutics, INC. | $15.53 | 2021 | |
| Boston Scientific Corporation | $14.98 | 2022 | |
| Z-Medica, LLC | $8.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Anreddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.